LA	locally advanced
BC	breast cancer
HR+	hormone receptor positive
pCR	pathological complete response
NCT	neoadjuvant chemotherapy
NET	neoadjuvant endocrine therapy
ER	estrogen receptors
PgR	progesterone receptors
HER2-	hormone epidermal growth factor 2 negative
TN	triple negative
BCS	breast conservative surgery
ObR	objective response
PEPI	preoperative endocrine prognostic index
DBs	databases
CENTRAL	Cochrane Central Register of Controlled Trials
MeSH	Medical Subject Headings
ASCO	American Society of Clinical Oncology
AACR	American Association of Cancer Research
OS	overall survival
OR	odds ratio
CI	confidence interval
DFS	disease free survival
ORR	overall response rate
EC	epirubicin-cyclophosphamide
RFS	relapse free survival
pATR	phosphorylated ataxia-teleangectasia and Rad3-related protein
ATM	phosphorylated ataxia-telangiectasia mutated
γ-H2AX	phosphorylated H2A Histone Family Member X
CCCA	complete cell cycle arrest
RCB	residual cancer burden
eBC	early breast cancer
PI3K	phosphatidylinositol-4,5-bisphosphate 3-kinase
PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
AKT1	RAC-alpha serine/threonine-protein kinase
PTEN	Phosphatase and tensin homolog
FGFR1	fibroblast grow factor receptor 1
TILs	Tumor-infiltrating lymphocytes
PD-L1	Programmed death-ligand 1
PD-1	Programmed death-1
POAI	peri-operative aromatase inhibitor
TTR	time to recurrence
WoTs	window of opportunity trials
CDK4/6	cyclin-dependent kinase 4 and 6